Hancock Jaffe Laboratories Inc IPO év
Mi az Hancock Jaffe Laboratories Inc IPO év?
A IPO év az Hancock Jaffe Laboratories Inc - 1970
Mi a IPO év meghatározása?
A kezdeti nyilvános ajánlattétel olyan nyilvános ajánlattétel, amelyben a társaság részvényeit általában olyan intézményi befektetőknek adják el, akik viszont értékpapírcserében először értékesítik a nagyközönségnek.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
IPO év a Health Care szektor a NASDAQ-on cégekben a Hancock Jaffe Laboratories Inc -hoz képest
Mit csinál Hancock Jaffe Laboratories Inc?
Hancock Jaffe Laboratories specializes in developing and manufacturing bioprosthetic (tissue-based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product candidates: the VenoValveÒ, a porcine-based valve which is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency, and the CoreoGraftÒ, a bovine tissue-based off-the-shelf conduit intended to be used for coronary artery bypass surgery.
ipo év -hoz hasonló cégek Hancock Jaffe Laboratories Inc
- Vanguard FTSE Developed Europe ex UK ETF nak IPO év 1969 van
- Hancock Jaffe Laboratories Inc nak IPO év 1970 van
- PepsiCo Inc nak IPO év 1972 van
- Applied Materials nak IPO év 1972 van
- L&T Finance nak IPO év 1972 van
- Coca-Cola Consolidated Inc nak IPO év 1972 van
- GT Biopharma nak IPO év 1972 van
- Jacobs Solutions Inc nak IPO év 1972 van